nach oben

Erschienen in:

01.06.2022 | editorial

New targeted therapies/small molecules in oncology and hematology

verfasst von: Assoc.-Prof. PD Dr. Anna Sophie Berghoff

Einloggen, um Zugang zu erhalten

Auszug

In this issue of the Magazine of European Medical Oncology (MEMO), we provide a series of articles on new targeted therapies and small molecules. …

Feichtner A, Kugler V, Nuener T, Schwaighofer S, Fleischmann J, Stefan E. Tracking mutation and drug-driven alterations of oncokinase conformations. memo. 2022; https://doi.org/10.1007/s12254-021-00790-6.CrossRef

Mayrhofer K, Niedersüße-Beke D. New targeted therapies in kidney cancer. memo. 2022; https://doi.org/10.1007/s12254-021-00782-6.CrossRef

Aretin M‑B. Antibody drug conjugates—the magic bullets? memo. 2022; https://doi.org/10.1007/s12254-021-00780-8.CrossRef

Marhold M. Current state of clinical development of TROP2-directed antibody-drug conjugates for triple-negative breast cancer. memo. 2022; https://doi.org/10.1007/s12254-021-00781-7.CrossRef

Al Sharie AH, Al Zu’bia YO, Al Sharie S, Baydoun HA, Atawneh FH, Alshari O, et al. Systemic capillary leak syndrome following Granulocyte colony-stimulating factor therapy in a T-lymphoblastic leukemia/lymphoma patient: a case report. memo. 2022; https://doi.org/10.1007/s12254-021-00789-z.CrossRefPubMedPubMedCentral

Titel: New targeted therapies/small molecules in oncology and hematology
verfasst von: Assoc.-Prof. PD Dr. Anna Sophie Berghoff
Publikationsdatum: 01.06.2022
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 2/2022
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-022-00811-y